Comparing transcriptomic profiles from seven cell lines to elucidate liver metastatic potential

Overview: The liver is a vital organ, performing over 500 functions. Metastasis to the liver can disrupt these functions, resulting in poor prognoses. It is not always clear why liver metastasis arises in one case but not another involving the same cancer type. We sought to understand which transcri...

Full description

Bibliographic Details
Main Authors: Lindsay R. Dresang, Christian A. Van Scoyk, Kirby J. Kuehn, Taylor A. Tauber, Arthur R. Tondin, Morgan A. Broske, Cody J. Schreiner
Format: Article
Language:English
Published: Elsevier 2022-07-01
Series:Advances in Cancer Biology - Metastasis
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2667394021000186
_version_ 1818252893638098944
author Lindsay R. Dresang
Christian A. Van Scoyk
Kirby J. Kuehn
Taylor A. Tauber
Arthur R. Tondin
Morgan A. Broske
Cody J. Schreiner
author_facet Lindsay R. Dresang
Christian A. Van Scoyk
Kirby J. Kuehn
Taylor A. Tauber
Arthur R. Tondin
Morgan A. Broske
Cody J. Schreiner
author_sort Lindsay R. Dresang
collection DOAJ
description Overview: The liver is a vital organ, performing over 500 functions. Metastasis to the liver can disrupt these functions, resulting in poor prognoses. It is not always clear why liver metastasis arises in one case but not another involving the same cancer type. We sought to understand which transcripts and cellular pathways are dysregulated in cell lines shown to metastasize substantially to the liver in a NOD-Scid-Gamma (NSG) mouse-xenograft model. Cancer cell lines of the same type not observed to metastasize to the liver were used for comparison, reducing cell type-specific changes or general pathways associated with cancer not linked to liver metastasis. Three metastatic versus non-metastatic pairs of diverse origin–Merkel cell, colorectal, and pancreatic carcinomas–as well as a normal fibroblast control were used for deep sequencing and transcriptome analysis with subsequent pathway identification. Results: Dysregulated pathways involve cell adhesion, proliferation, and motility (among others), which are consistent with increased malignant potential in the cell lines that support liver metastasis. In addition, dysregulated peroxisome proliferating activated receptor (PPAR) signaling and lipid metabolic / trafficking pathways are candidates for fostering homing to the liver. A surprise was a significant drop in AGR2 expression in cells favoring liver metastasis, while still remaining elevated relative to normal fibroblast controls. Newer clinical data revealed declining levels of AGR2 correlate with higher grade lesions and poorer prognoses in patients with various cancer types. Decreased expression of FOXA2 similarly correlates with clinical data as a prognostic factor. A drop in FOXA2 expression was observed in cell lines favoring liver metastasis, as well as a cell line generated from an NSG-xenograft liver metastasis, which may also explain the liver site preference of select cancer cell lines. Both genes correlate with PPAR signaling dysregulation and either directly or indirectly link to such pathways. Meanwhile, LOXL2 is lower in the cancer cell lines supporting liver metastasis compared to normal fibroblasts, but is substantially elevated relative to paired cancer cell lines which did not metastasize to the liver. LOXL2 is a gene involved in epithelial-mesenchymal transition (EMT), which is expressed at high levels in both normal and cancer-associated fibroblasts. Conclusions: Using only a normal fibroblast control for comparison, or only comparing cancer cells as separate pairs, would have masked several potential candidate genes and pathways linked to liver metastasis. Our findings correlate well with newer clinical data and reinforce biomarkers of disease progression. The dysregulated genes and pathways highlight potential targets to slow disease progression.
first_indexed 2024-12-12T16:31:25Z
format Article
id doaj.art-1caf6457c9f74f86b957279893c18ca8
institution Directory Open Access Journal
issn 2667-3940
language English
last_indexed 2024-12-12T16:31:25Z
publishDate 2022-07-01
publisher Elsevier
record_format Article
series Advances in Cancer Biology - Metastasis
spelling doaj.art-1caf6457c9f74f86b957279893c18ca82022-12-22T00:18:46ZengElsevierAdvances in Cancer Biology - Metastasis2667-39402022-07-014100018Comparing transcriptomic profiles from seven cell lines to elucidate liver metastatic potentialLindsay R. Dresang0Christian A. Van Scoyk1Kirby J. Kuehn2Taylor A. Tauber3Arthur R. Tondin4Morgan A. Broske5Cody J. Schreiner6University of Wisconsin-Stevens Point, USA; Corresponding author. University of Wisconsin-Stevens Point, Dept. of Biology, CBB Bldg. Rm. 313, 2101 Fourth Ave., Stevens Point, WI, 54481-3897, USA.University of Wisconsin-Stevens Point, USA; Pharmaceutical Product Development, USAUniversity of Wisconsin-Stevens Point, USAUniversity of Wisconsin-Stevens Point, USA; Arizona State University, USAUniversity of Wisconsin-Stevens Point, USA; University of Miami, USAUniversity of Wisconsin-Stevens Point, USA; West Virginia School of Osteopathic Medicine, USAUniversity of Wisconsin-Stevens Point, USA; Medical College of Wisconsin-Central Wisconsin, USAOverview: The liver is a vital organ, performing over 500 functions. Metastasis to the liver can disrupt these functions, resulting in poor prognoses. It is not always clear why liver metastasis arises in one case but not another involving the same cancer type. We sought to understand which transcripts and cellular pathways are dysregulated in cell lines shown to metastasize substantially to the liver in a NOD-Scid-Gamma (NSG) mouse-xenograft model. Cancer cell lines of the same type not observed to metastasize to the liver were used for comparison, reducing cell type-specific changes or general pathways associated with cancer not linked to liver metastasis. Three metastatic versus non-metastatic pairs of diverse origin–Merkel cell, colorectal, and pancreatic carcinomas–as well as a normal fibroblast control were used for deep sequencing and transcriptome analysis with subsequent pathway identification. Results: Dysregulated pathways involve cell adhesion, proliferation, and motility (among others), which are consistent with increased malignant potential in the cell lines that support liver metastasis. In addition, dysregulated peroxisome proliferating activated receptor (PPAR) signaling and lipid metabolic / trafficking pathways are candidates for fostering homing to the liver. A surprise was a significant drop in AGR2 expression in cells favoring liver metastasis, while still remaining elevated relative to normal fibroblast controls. Newer clinical data revealed declining levels of AGR2 correlate with higher grade lesions and poorer prognoses in patients with various cancer types. Decreased expression of FOXA2 similarly correlates with clinical data as a prognostic factor. A drop in FOXA2 expression was observed in cell lines favoring liver metastasis, as well as a cell line generated from an NSG-xenograft liver metastasis, which may also explain the liver site preference of select cancer cell lines. Both genes correlate with PPAR signaling dysregulation and either directly or indirectly link to such pathways. Meanwhile, LOXL2 is lower in the cancer cell lines supporting liver metastasis compared to normal fibroblasts, but is substantially elevated relative to paired cancer cell lines which did not metastasize to the liver. LOXL2 is a gene involved in epithelial-mesenchymal transition (EMT), which is expressed at high levels in both normal and cancer-associated fibroblasts. Conclusions: Using only a normal fibroblast control for comparison, or only comparing cancer cells as separate pairs, would have masked several potential candidate genes and pathways linked to liver metastasis. Our findings correlate well with newer clinical data and reinforce biomarkers of disease progression. The dysregulated genes and pathways highlight potential targets to slow disease progression.http://www.sciencedirect.com/science/article/pii/S2667394021000186OncologyCancer cell linesLiver metastasesBioinformaticsTranscriptomic profilesGene ontology
spellingShingle Lindsay R. Dresang
Christian A. Van Scoyk
Kirby J. Kuehn
Taylor A. Tauber
Arthur R. Tondin
Morgan A. Broske
Cody J. Schreiner
Comparing transcriptomic profiles from seven cell lines to elucidate liver metastatic potential
Advances in Cancer Biology - Metastasis
Oncology
Cancer cell lines
Liver metastases
Bioinformatics
Transcriptomic profiles
Gene ontology
title Comparing transcriptomic profiles from seven cell lines to elucidate liver metastatic potential
title_full Comparing transcriptomic profiles from seven cell lines to elucidate liver metastatic potential
title_fullStr Comparing transcriptomic profiles from seven cell lines to elucidate liver metastatic potential
title_full_unstemmed Comparing transcriptomic profiles from seven cell lines to elucidate liver metastatic potential
title_short Comparing transcriptomic profiles from seven cell lines to elucidate liver metastatic potential
title_sort comparing transcriptomic profiles from seven cell lines to elucidate liver metastatic potential
topic Oncology
Cancer cell lines
Liver metastases
Bioinformatics
Transcriptomic profiles
Gene ontology
url http://www.sciencedirect.com/science/article/pii/S2667394021000186
work_keys_str_mv AT lindsayrdresang comparingtranscriptomicprofilesfromsevencelllinestoelucidatelivermetastaticpotential
AT christianavanscoyk comparingtranscriptomicprofilesfromsevencelllinestoelucidatelivermetastaticpotential
AT kirbyjkuehn comparingtranscriptomicprofilesfromsevencelllinestoelucidatelivermetastaticpotential
AT tayloratauber comparingtranscriptomicprofilesfromsevencelllinestoelucidatelivermetastaticpotential
AT arthurrtondin comparingtranscriptomicprofilesfromsevencelllinestoelucidatelivermetastaticpotential
AT morganabroske comparingtranscriptomicprofilesfromsevencelllinestoelucidatelivermetastaticpotential
AT codyjschreiner comparingtranscriptomicprofilesfromsevencelllinestoelucidatelivermetastaticpotential